Revance Therapeutics (NASDAQ:RVNC) Stock Rating Upgraded by StockNews.com
Revance Therapeutics (NASDAQ:RVNC) Stock Rating Upgraded by StockNews.com
Revance Therapeutics (NASDAQ:RVNC – Get Rating) was upgraded by StockNews.com from a "sell" rating to a "hold" rating in a report issued on Monday.
在周一发布的一份报告中,斯托克新闻网站将Revance治疗公司(纳斯达克:RVNC-GET评级)从“卖出”评级上调为“持有”评级。
A number of other research analysts have also recently commented on the stock. Cowen boosted their target price on shares of Revance Therapeutics from $55.00 to $65.00 in a research report on Thursday, September 8th. Mizuho boosted their target price on shares of Revance Therapeutics from $26.00 to $30.00 and gave the stock a "buy" rating in a research report on Friday, September 9th. Barclays boosted their target price on shares of Revance Therapeutics from $22.00 to $35.00 and gave the stock an "overweight" rating in a research report on Friday, September 9th. Wells Fargo & Company boosted their target price on shares of Revance Therapeutics from $17.00 to $24.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 25th. Finally, Cowen boosted their target price on shares of Revance Therapeutics from $55.00 to $65.00 in a research report on Thursday, September 8th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $39.75.
其他一些研究分析师最近也对该股发表了评论。考恩在9月8日星期四的一份研究报告中将Revance治疗公司的股票目标价从55.00美元上调至65.00美元。瑞穗在9月9日周五的一份研究报告中将Revance Treeutics的股票目标价从26.00美元上调至30.00美元,并给予该股“买入”评级。巴克莱在9月9日周五的一份研究报告中将Revance Treateutics的股票目标价从22.00美元上调至35.00美元,并给予该股“增持”评级。富国银行在8月25日星期四的一份研究报告中将Revance治疗公司的股票目标价从17.00美元上调至24.00美元,并给予该股“同等权重”的评级。最后,考恩在9月8日星期四的一份研究报告中将Revance治疗公司的股票目标价从55.00美元上调至65.00美元。两名股票研究分析师对该股的评级为持有,四名分析师对该公司的评级为买入。根据MarketBeat.com的数据,该公司的普遍评级为“适度买入”,平均目标价为39.75美元。
Revance Therapeutics Trading Down 2.3 %
Revance治疗公司股价下跌2.3%
Shares of RVNC stock opened at $26.01 on Monday. The stock has a market cap of $1.90 billion, a price-to-earnings ratio of -6.76 and a beta of 0.92. The company has a quick ratio of 3.20, a current ratio of 3.38 and a debt-to-equity ratio of 14.80. Revance Therapeutics has a fifty-two week low of $11.27 and a fifty-two week high of $30.00. The firm's 50 day moving average price is $20.27 and its two-hundred day moving average price is $17.40.
周一,RVNC的股票开盘报26.01美元。该股市值为19亿美元,市盈率为-6.76倍,贝塔系数为0.92。该公司的速动比率为3.20,流动比率为3.38,债务权益比为14.80。Revance Treeutics的股价为52周低点11.27美元,52周高点为30.00美元。该公司的50日移动均线价格为20.27美元,200日移动均线价格为17.40美元。
Insider Buying and Selling
内幕买卖
In related news, SVP Dwight Moxie sold 11,000 shares of Revance Therapeutics stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $27.07, for a total value of $297,770.00. Following the completion of the sale, the senior vice president now owns 31,694 shares in the company, valued at $857,956.58. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 5.10% of the company's stock.
在相关新闻中,高级副总裁德怀特·莫克西在9月14日星期三的一次交易中出售了1.1万股Revance Treateutics股票。这些股票的平均价格为27.07美元,总价值为297,770.00美元。出售完成后,高级副总裁现在拥有该公司31,694股,价值857,956.58美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,可以通过以下链接访问该文件。内部人士持有该公司5.10%的股份。
Institutional Trading of Revance Therapeutics
Revance治疗药物的制度性交易
Several institutional investors have recently added to or reduced their stakes in RVNC. Dimensional Fund Advisors LP increased its stake in Revance Therapeutics by 7.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 131,661 shares of the biopharmaceutical company's stock valued at $2,149,000 after purchasing an additional 8,801 shares during the last quarter. Teacher Retirement System of Texas increased its stake in Revance Therapeutics by 18.6% during the fourth quarter. Teacher Retirement System of Texas now owns 12,940 shares of the biopharmaceutical company's stock valued at $211,000 after purchasing an additional 2,032 shares during the last quarter. Panagora Asset Management Inc. bought a new stake in Revance Therapeutics during the fourth quarter valued at $175,000. Rafferty Asset Management LLC increased its stake in Revance Therapeutics by 88.7% during the fourth quarter. Rafferty Asset Management LLC now owns 14,724 shares of the biopharmaceutical company's stock valued at $240,000 after purchasing an additional 6,923 shares during the last quarter. Finally, MAI Capital Management bought a new stake in Revance Therapeutics during the fourth quarter valued at $193,000. Institutional investors own 77.08% of the company's stock.
几家机构投资者最近增持或减持了RVNC的股份。Dimension Fund Advisors LP在第四季度将其在Revance Treateutics的股份增加了7.2%。Dimension Fund Advisors LP现在拥有这家生物制药公司131,661股股票,价值2,149,000美元,此前在上个季度又购买了8,801股。德克萨斯州教师退休系统在第四季度将其在Revance Treeutics的股份增加了18.6%。德克萨斯州教师退休系统现在拥有这家生物制药公司12,940股票,价值211,000美元,在上个季度购买了另外2,032股票。PanAgora资产管理公司在第四季度购买了Revance Treateutics的新股份,价值17.5万美元。Rafferty Asset Management LLC在第四季度将其在Revance Treateutics的股份增加了88.7%。Rafferty Asset Management LLC现在拥有这家生物制药公司14,724股股票,价值240,000美元,上个季度又购买了6,923股。最后,Mai Capital Management在第四季度购买了Revance Treeutics的新股份,价值19.3万美元。机构投资者持有该公司77.08%的股份。
About Revance Therapeutics
关于Revance Treeutics
(Get Rating)
(获取评级)
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
Revance治疗公司是一家生物技术公司,在美国和国际上从事各种美学和治疗适应症的神经调节剂的开发、制造和商业化。该公司的主要候选药物是注射用达西肉毒毒素A,该药已完成治疗眉间(眉)纹和颈肌张力障碍的III期临床试验;正在进行治疗上面部线条、中度或重度动感额线和中重度外眼角线条的II期临床试验;已完成治疗成人上肢痉挛和足底筋膜炎的II期临床试验。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Revance Therapeutics (RVNC)
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Has AMD stock stock fallen too far?
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- 免费获取StockNews.com关于Revance Treeutics(RVNC)的研究报告
- Roku股票下跌,但并未出局
- 福特在第三季度发出警告后是否正在反弹
- 如果你渴望价值,那就尝尝露丝的好客之道吧
- AMD股票是不是跌得太厉害了?
- 甲骨文的短期痛苦可能是你的长期收益
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Revance Treateutics Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Revance Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。